Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Akers Biosciences surges after beefing up commercial team

The two recruits have skill sets that are highly relevant to Akers's commercial strategy
Akers Biosciences surges after beefing up commercial team
Akers develops and supplies rapid screening and testing products

Akers Biosciences (LON:AKR, NASDAQ:AKER), a developer of health information technologies, has strengthened its commercial team with two sales and marketing recruits.

Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.

Carrara has over 25 years' experience in the clinical diagnostics arena, particularly within sales, marketing and global operations. He joins Akers Bio from Quest Diagnostics where he was the senior director of Strategic Accounts, leading a team of directors responsible for developing and implementing strategic relationships within the acute care market.

Saporito has a track record of building and leading high-performance businesses in the medical device and clinical diagnostics arenas for two decades. Prior to joining Akers Bio, he held the role of strategic account executive with The Midmark Corporation, where he was responsible for driving new business through group purchasing organisations, integrated health systems and distribution.

“Their skill sets are highly relevant to our commercial strategy for growing product sales over the coming years and we are very excited to have them on board," said Raymond Akers, co-founder and executive chairman of the dual-listed medical screening and testing products developer.

Chief executive John Gormally said: "Having worked with both Douglas and Tony at Becton Dickinson, I have direct experience of their first class abilities to execute highly profitable sales strategies.

"Douglas will be instrumental in building an evidence-based outcome value proposition marketing strategy, particularly to support the growth of Akers Bio's flagship test for heparin-induced thrombocytopenia. Tony will lead the channel management strategy for Akers Bio in the US as we develop highly engaged, integrated business plans with our customers and distribution partners that enhance mutual gains in efficiency, productivity and profitability," he said.

Shares in Akers surged 7.7% to 105p on news of the announcements.

John-H.jpg
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

Related Articles

AZN3.jpg
March 23 2016
Douglas Carrara has joined as vice president of Global Marketing and Commercial Operations, while Tony Saporito has been brought in as vice president of US Sales and Distribution.
AZN2.jpg
March 31 2016
Amryt Pharmaceuticals will join the London market in a deal that values it at £29.6mln. A share placing, meanwhile, will bring in £10mln to be used to develop the company’s lead treatment for a rare skin disorder.
1-Operation.jpg
April 12 2016
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.